26.9 C
Vientiane
Monday, May 5, 2025
spot_img
Home Blog Page 412

HKA WELCOMES ADAM SMITH AS A PRINCIPAL IN THE ADVISORY TEAM IN AUSTRALIA

SYDNEY, March 6, 2025 /PRNewswire/ — HKA, a leading infrastructure project, strategy, commercial advisory and dispute resolution company, is delighted to announce the appointment of Adam Smith to our Advisory team in Australia. Adam joins our Brisbane office and brings with him over 20 years of experience across multiple industries, including transport infrastructure, defence, and renewable energy.

Adam Smith, Principal HKA
Adam Smith, Principal HKA

Adam is a dynamic and results-driven professional, with extensive experience leading strategic initiatives, shaping commercial and financial strategies, and delivering complex infrastructure projects. Adam has a proven track record of transforming vision into action by driving operational excellence and fostering a culture of continuous improvement.

Dafydd Wyn Owen, Partner and Advisory Lead, International expressed his enthusiasm about Adam’s appointment: “We are thrilled to welcome Adam to the HKA team. His extensive experience and strategic leadership will be invaluable as we continue to expand our advisory offerings in Queensland and across Australia. Adam’s ability to navigate complex business challenges and drive substantial growth aligns perfectly with our commitment to delivering exceptional value to our clients.”

Mike Pitt, Partner and Advisory Lead APAC added: “Adam’s expertise in leading organisations through transformational growth and his strong networks across Australia make him a perfect fit for our team. We look forward to leveraging his insights and experience to further enhance our advisory capabilities and support our clients’ success.”

Adam shared his excitement about joining HKA: “I’m excited to be joining HKA’s Advisory team and contributing to the organisation’s ongoing success. With a strong focus on delivering value to our clients, I look forward to leveraging my experience to help navigate complex challenges, drive strategic outcomes and support the delivery of critical infrastructure projects. Together, we will continue to push the boundaries of excellence and innovation in the industry.

Adam holds a Bachelor of Commerce, is a Fellow Chartered Accountant (FCA), and holds a Diploma of Applied Finance and Investment. He is also a Graduate of the Australian Institute of Company Directors (GAICD) and an Accredited Speaker with the National Speakers Association (Australia).

We are confident that Adam’s expertise and leadership will significantly contribute to the continued success and growth of HKA’s Advisory team in Australia. We look forward to the positive impact he will bring to our clients and our organisation.

For more information about HKA, visit www.hka.com

Contact: Peita Calvertpeitacalvert@hka.com 

Getac’s Next Generation B360 and B360 Pro Combine Powerful AI-Ready Technology with Fully Rugged Reliability for Exceptional Versatility and Performance

Both laptops also offer an extensive range of industry-specific configurations and customisation flexibility*, meaning customers can tailor devices to their exact needs

News in brief:

  • Getac’s next generation B360 and B360 Pro are the first fully rugged laptops to feature the latest Intel® CoreTM Ultra Series 2 processors and Intel® AI Boost technology.
  • Both devices enable users to leverage on-device Edge AI to quickly and seamlessly execute tasks in scenarios requiring real-time processing, high levels of data privacy and security, offline capability, and cost efficiency.
  • The B360 is ideally suited to professionals working in the public safety and utility sectors, while the B360 Pro is built with the unique needs of defence professionals in mind.

TAIPEI, March 6, 2025 /PRNewswire/ — Getac Technology Corporation (Getac), a leading provider of rugged computing and mobile video solutions, today announced the launch of its next generation B360 and B360 Pro fully rugged laptops, offering professionals across industries including public safety, utilities and defence two powerful, yet versatile solutions to overcome the daily challenges they face.

The next generation B360 and B360 Pro combine fully rugged build quality with a host of innovative new technology upgrades.
The next generation B360 and B360 Pro combine fully rugged build quality with a host of innovative new technology upgrades.

Next generation AI-ready performance

The next generation B360 and B360 Pro combine fully rugged build quality with a host of innovative new technology upgrades. This includes the latest Intel® CoreTM Ultra Series 2 processors and Intel® AI Boost technology, which enables users to leverage on-device Edge AI to quickly and seamlessly execute tasks. In a recent text-to-report evaluation test conducted with Getac industry customers using Llama 3.1 8B, AI applications running on the B360 were able to turn extensive texts into full reports in a matter of seconds. This powerful Edge AI performance offers significant operational advantages over cloud AI, particularly in scenarios requiring real-time processing, high levels of data privacy and security, offline capability, and cost efficiency.

Elsewhere, the next generation B360 and B360 Pro boast a range of versatile new I/O options, including up to two ThunderboltTM 4 ports for incredibly fast data transfer. LifeSupport hot-swappable battery technology boosts productivity by minimising the need to recharge the devices mid-shift, while WiFi 7 offers data speeds up to five times faster than WiFi 6, as well as up to 60% lower latency.

The B360 Pro features dual high-capacity batteries as standard, while an optional NVIDIA Quadro RTX A500 4GB discrete graphics controller takes visuals to the next level without impacting processing performance. The B360 Pro also includes an optional media bay, which can accommodate a third SSD (for up to 6TB storage capacity in total), third battery, DVD drive or Blu-Ray drive as required.

Fully customisable to meet specific industry needs

The next generation B360 and B360 Pro are both available in a range of industry-specific configurations and can be further tailored with bespoke customisation options* spanning hardware, software, accessories and service. As a result, customers can ensure their device specifications match intended use cases, even when only ordering in small batches. Key industry examples include:

  • Optimal situational awareness for public safety professionals

Situational awareness is paramount for public safety professionals such as police patrol units, where officers rely on their Getac rugged devices for secure, fast data access and real-time intelligence updates while in the field. Public safety organisations can customise their next generation B360 devices with a range of specific software, hardware, accessory and service options* to fully optimise their situational awareness capabilities. Software options such as Getac Geolocation can be specified for more accurate location information, while the addition of multiple optional device authentication layers, such as password, RFID reader and a fingerprint reader help ensure seamless device access while maintaining data security at all times. Additional accessories, including a secure vehicle dock and high-capacity batteries further enhance device usability in the field, while keeping downtime to a minimum.

  • Highly efficient mobile GIS, surveying and mapping for utilities professionals

The next generation B360 is ideally suited to mobile GIS, surveying and mapping tasks in remote locations and/or adverse weather conditions, thanks to its MIL-STD-810H, MIL-STD-461G, and IP66 certifications, as well as 6ft drop resistance. An optional secure carry bag aids portability, while software such as Getac Virtual GPS Utility offers a fast and reliable way to manage up to five GPS applications simultaneously. If even more accuracy is required, the next generation B360 can also be equipped with an optional high accuracy GPS module and antenna, ensuring location accuracy to the greatest extent.

  • Secure, reliable command and control for defence professionals

In the defence industry, commanders rely on Getac rugged devices for real-time intelligence, military data integration, and secure communications to drive mission critical decisions and counter threats. The next generation B360 Pro features extended battery life as standard for uninterrupted operation in the field, while an optional secure vehicle dock can quickly turn any vehicle into a mobile command station. The B360 Pro can also be customised to include two PCMCIA readers* if needed (one is included as standard), further increasing device functionality without the need for external adaptors.

“As the popularity of open-source and Mixture-of-Experts (MoE) language models continues to grow at a rapid pace, we have collaborated with industry customers to develop innovative vertical market AI applications that enable them to take full advantage of the operational benefits on offer. These advancements will drive demand for rugged Edge AI devices like the next generation B360 and B360 Pro, and accelerate AI adoption across the public safety, utilities and defence sectors,” says James Hwang, President of Getac Technology Corporation. “Our industry-specific solutions and customisation capabilities also give customers much more control when choosing devices for specific use cases, helping to maximise productivity and ensure a rapid return on their investment.”

The next generation B360 and B360 Pro will be available in April.

For more information, please visit www.getac.com

*Additional charges apply

About Getac

Getac Technology Corporation is a global leader in AI-capable rugged mobile technology and intelligent video solutions, including laptops, tablets, software, body-worn cameras, in-car video systems, digital evidence management and enterprise video analytics solutions. Getac’s solutions and services are designed to enable extraordinary experiences for frontline workers in challenging environments. Today, Getac serves customers in over 100 countries spanning defence, public safety, ambulance, fire & rescue, utilities, automotive, natural resources, manufacturing, transport, and logistics. Getac was recently recognized as one of Newsweek’s “World’s Most Trustworthy Companies” for 2024. For more information, visit: http://www.getac.com. Participate in the Getac Industry blog or follow the company on LinkedIn and YouTube

Getac and Getac logo are trademarks of Getac Holdings Corporation or its affiliates. Other brands or trademarks are the property of their respective owners. ©2025 Getac Technology Corporation.

SOL ARENA USHERS IN A NEW ERA OF CASUAL GAMING AND CRYPTO WAGERING ON SOLANA, WITH $CHILL TOKEN LAUNCHING SOON

  • SOL Arena, the Web3 multiplayer battle game developed by Chillchat, will launch its $CHILL token at end-March 2025, following its sold-out Challengers NFT mint on Magic Eden on February 6, 2025.
  • Delivering a fresh take on snake-like gameplay on the Solana blockchain, SOL Arena has attracted 80,000+ global players since its Open Beta launch in September 2024.
  • Backed by Solana Ventures, Crypto.com Capital, and Big Brain Holdings, Chillchat aims to pioneer innovation in Web3 gaming by marrying casual gameplay with high-stakes crypto wagering in massive real-time battles.

BANGKOK, March 6, 2025 /PRNewswire/ — SOL Arena, a high-stake multiplayer battle game powered by Solana and now live in Open Beta, will launch its $CHILL token at end-March 2025, which will allow players to wager $CHILL in real-time crypto battles, or stake for in-game and ecosystem rewards. After welcoming more than 80,000 players worldwide since its Open Beta began on September 20, 2024, SOL Arena’s highly anticipated $CHILL token launch follows a sold-out Challengers NFT mint on Magic Eden last month.

SOL Arena, the Web3 multiplayer battle game developed by Chillchat Games, will launch its $CHILL token at end-March 2025.
SOL Arena, the Web3 multiplayer battle game developed by Chillchat Games, will launch its $CHILL token at end-March 2025.

Developed by Chillchat, a Bangkok-based Web3 gaming studio, SOL Arena unites casual snake-style gameplay with massive real-time battles and large-scale crypto wagering. By pairing the simplicity of casual gaming with the thrill of real crypto stakes, SOL Arena delivers a fresh take on Web3 gaming on Solana — appealing to both casual gamers and competitive enthusiasts.

To support its continued growth and development, Chillchat previously secured US$8.69M in seed funding, led by Solana Ventures, Crypto.com Capital, and Big Brain Holdings. Matt Beck, Head of Investments at Solana Ventures said: “SOL Arena is introducing a new way to engage with crypto gaming — where every match matters because there’s something real at stake. This is exactly the kind of innovation that will drive Web3 gaming forward.”

SOL Big Brain of Big Brain Holdings said: “I’m hyped to see how SOL Arena evolves over time. Its approach to merging casual gaming with real-time wagering is already making waves in the Solana community.”

A New Era of Web3 Gaming: Real-Time Crypto Wagering at Scale
SOL Arena merges the simplicity of popular multiplayer snake games with intense extraction gameplay, allowing up to 50 players to compete in real-time battles to collect noCHILL, outmaneuver opponents, and strategically withdraw their winnings. The upcoming High Roller Mode will introduce crypto wagering with $CHILL, raising the stakes for both casual players and high-level competitors. SOL Arena integrates the dynamic, community-driven Solana ecosystem directly into the game, where memecoin projects, NFT communities, and token holders unite under shared teams.

“Our vision is to merge casual gaming with degenerate memecoin activity and crypto network effects,” said James Au, CEO and Game Director of Chillchat, “to deliver an exciting new player experience that redefines the thrill of ‘winning’.”

What’s Next? Token Launch and Mobile Play
Following the Challengers NFT mint in February 2025, SOL Arena’s next significant milestone is the launch of its ecosystem token, $CHILL, at the end of March.

The $CHILL token fuels SOL Arena’s in-game economy, allowing players to wager it in High Roller mode, or stake it to earn in-game rewards. Players can qualify for a $CHILL airdrop by playing the game and extracting noCHILL, or by holding Chillchat Origin or SOL Arena Challengers’ NFTs.

The official launch of the SOL Arena game, which will introduce new features such as Seasons, will include mobile versions for both iOS and Android available in mid-2025.

Join the SOL Arena Battles Now
SOL Arena is free to play now at solarena.io. Jump in, collect and extract noCHILL, and start climbing the leaderboards to secure your spot in the upcoming $CHILL airdrop.

For more on SOL Arena:
Website
Discord
X (Twitter)
Telegram

About Chillchat
Chillchat is a Bangkok-based Web3 gaming studio dedicated to creating fun, accessible, and innovative blockchain-powered experiences. SOL Arena is the studio’s flagship title, merging traditional gaming fundamentals with real crypto stakes, all secured by Solana’s lightning-fast network. With an aim to pioneer the next generation of Web3 gaming, Chillchat invests in bold ideas that blend community engagement, financial incentives, and immersive gameplay.

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 6, 2025 /PRNewswire/ — Akeso, Inc. (9926. HK) (“Akeso” or the “Company”) is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world’s first PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk following curative resection or ablation.

The completion of patient enrollment in the COMPASSION-22/AK104-306 trial marks a significant milestone in the clinical development of cadonilimab for HCC. In addition to this Phase III study, another Phase III trial investigating cadonilimab in combination with lenvatinib and transarterial chemoembolization (TACE) for the treatment of unresectable intermediate to advanced HCC is currently progressing on schedule. The extensive exploration of combination therapies involving cadonilimab for HCC is expected to offer more effective treatment options for both early-stage and advanced HCC patients.

HCC is one of the most common malignant tumors globally. According to 2024 data, there are about 865,000 new cases of liver cancer worldwide, with 370,000 occurring in China. The recurrence rate after surgery is high, especially in patients with high-risk factors, with a five-year recurrence rate exceeding 70%. Currently, no standard adjuvant treatment exists for HCC in clinical practice. Identifying effective adjuvant therapies to reduce recurrence risk and extend survival is a critical unmet need in HCC treatment.

Cadonilimab is the world’s first approved bispecific immunotherapy for cancer. Previous studies have shown its significant efficacy and favorable safety profile in treating HCC. Research presented at the 2023 European Society for Medical Oncology (ESMO) Asia Annual Meeting demonstrated that cadonilimab combined with FOLFOX-HAIC as neoadjuvant therapy for resectable multinodular HCC achieved a 100% disease control rate (DCR) with manageable safety. Furthermore, data from the 2023 ESMO Congress highlighted that cadonilimab combined with lenvatinib as a first-line treatment for advanced HCC showed superior antitumor activity compared to approved therapies, effectively controlling tumor progression and offering long-term survival benefits over current treatment options.

Akeso will continue to advance cadonilimab clinical development for multiple malignant tumors, with the aim to provide more therapeutic options for patients worldwide. Currently, cadonilimab is currently involved in over 23 clinical studies across 16 indications, including gastric cancer, lung cancer, liver cancer, cervical cancer, and pancreatic cancer. It has already received approval for the treatment of recurrent/metastatic cervical cancer and first-line gastric cancer. The sNDA for cadonilimab for the treatment of first-line cervical cancer is currently under review. Additionally, five Phase III trials for HCC, non-small cell lung cancer (NSCLC), and gastric cancer are underway. Studies across multiple indications, including cervical cancer, gastric cancer, and NSCLC, have shown that cadonilimab offers meaningful efficacy benefits in all patient populations, regardless of PD-L1 expression levels (high, low, or negative). These patient data indicates that cadonilimab can also significantly broadens the eligible patient population that can benefit from cancer immunotherapies.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 23 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally, 5 new drugs are commercially available, and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

  • Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.
  • CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types.

SUZHOU, China, March 6, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL. CS5001 is also being evaluated as both a monotherapy and in combination with a PD-L1 inhibitor for advanced solid tumors in an ongoing global multi-center clinical trial.

Building on promising data from CS5001 monotherapy in later-line aggressive and indolent lymphomas, this Phase Ib trial aims to expand the therapeutic potential of CS5001 across all DLBCL stages and solid tumors. The study will explore:

  • CS5001 + R-CHOP: First-line treatment for DLBCL patients who have not received prior systemic therapy.
  • CS5001 + SoC: For patients with relapsed or refractory DLBCL.
  • CS5001 Monotherapy: Targeting ROR1-expressing solid tumors.
  • CS5001 + Sugemalimab: Combination therapy for advanced solid tumors.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated: “We are thrilled to reach another key clinical milestone for CS5001. The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II trial for first-line DLBCL. As we advance from late-line monotherapy to frontline combination therapy, we are optimistic that CS5001 will provide significant clinical benefits to DLBCL patients and establish itself as a first-line treatment option. Meanwhile, we continue to explore CS5001’s potential in solid tumors and eagerly anticipate further positive outcomes.”

The global multi-center Phase Ib trial for CS5001 is actively enrolling patients across the United States, Australia, and China. Recruitment is ongoing for monotherapy cohorts targeting aggressive and indolent advanced lymphomas, which could potentially expand into a Phase II single-arm registrational study. Additional cohorts, including the first-line DLBCL combination therapy and solid tumor monotherapy and combination therapy arms, will be initiated soon.

About CS5001 (ROR1 ADC)

CS5001 is a clinical-stage antibody-drug conjugate (“ADC”) targeting ROR1 (receptor tyrosine kinase-like orphan receptor 1). CS5001 has been uniquely designed with proprietary tumor-cleavable linker and pyrrolobenzodiazepine (“PBD”) prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps address the toxicity associated with traditional PBD payloads, leading to a better safety profile. CS5001 has demonstrated complete tumor suppression in several preclinical cancer models and demonstrated favorable serum half-life and pharmacokinetic characteristics. CS5001 is a promising candidate drug with precision treatment potential in both hematologic tumors and malignant solid tumors. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio of which enables homogeneous production and large-scale manufacturing.

In October 2020, CStone signed a licensing agreement with LigaChem Biosciences, Inc. (LCB) for the development and commercialization of CS5001 which was originally generated by collaboration of LCB and ABL Bio, both South Korea-based leading biotech companies. Under the agreement, CStone obtains the exclusive global right to develop and commercialize CS5001 outside the Republic of Korea.

The first-in-human data for CS5001 in patients with advanced solid tumors and lymphomas was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Additionally, the latest clinical data on CS5001 as a monotherapy in patients with advanced lymphomas has recently been presented at the 66th American Society of Hematology (ASH) Annual Meeting.

CS5001 has demonstrated encouraging safety and robust anti-tumor activity in the Phase 1a dose escalation trials across 10 dose levels.

  • At the tentative recommended Phase 2 dose (RP2D) of DL8 (125 μg/kg), CS5001 achieved objective response rates (ORRs) of 70% in advanced B-cell lymphoma and 100% in Hodgkin lymphoma.
  • Encouraging efficacy signals were also observed in advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
  • CS5001 was well tolerated in heavily pre-treated patients with advanced B-cell lymphomas and solid tumors.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

FARMLORE IN BENGALURU IS UNVEILED AS THE WINNER OF THE AMERICAN EXPRESS ONE TO WATCH AWARD 2025 AS PART OF ASIA’S 50 BEST RESTAURANTS

LONDON, March 6, 2025 /PRNewswire/ — Farmlore in Bengaluru has been honoured as the 2025 recipient of the prestigious American Express One To Watch Award. Selected by the 50 Best team based on the votes of its Academy and specific editorial criteria, this award highlights dining establishments that showcase exceptional culinary talent, creativity and the potential to secure a spot in the Asia’s 50 Best Restaurants list over the coming years.

Asia's 50 Best Restaurants announces Bengaluru-based restaurant Farmlore as the recipient of the American Express One To Watch Award 2025
Asia’s 50 Best Restaurants announces Bengaluru-based restaurant Farmlore as the recipient of the American Express One To Watch Award 2025

Farmlore, an 18-seater dining experience on a 37-acre farm near Bengaluru, India, is the brainchild of chef Johnson Ebenezer and entrepreneur Kaushik Raju. The restaurant embodies a farm-to-table ethos, driven by seasonality, sustainability and local produce. Its name cleverly combines ‘folklore’ and ‘locavore,’ reflecting its dedication to celebrating regional ingredients and cultural narratives.

William Drew, Director of Content for Asia’s 50 Best Restaurants, says: “Amid the restaurants with a ‘farm-to-table’ philosophy, Farmlore stands apart with its immersive experience, nestled within an actual working farm. We congratulate chef Johnson and the teams behind the kitchens and farms at Farmlore, on this very well-earned accolade.”

The restaurant’s menus, shaped by the freshest harvests from its farm, consistently highlight core themes, including a strong South Indian influence. Here they prioritise ethical, organic farming principles passed down through generations that also preserve soil health while creating nutrient-rich produce. The design harmonises with its natural surroundings, featuring earthy tones, open spaces and a minimalist aesthetic that fosters an intimate yet direct connection to nature.

On winning, Chef Johnson says, “We are truly humbled to be recognised by Asia’s 50 Best Restaurants. This award is a testament to our unwavering commitment to doing things the right way while staying true to our values and prioritising ethics over expediency. It’s also a testament to the younger generation of chefs who dare to stick to their strengths and roots.”

Farmlore will be further celebrated at the in-person awards ceremony held on 25 March 2025 in Seoul in collaboration with host destination partner, the Ministry of Agriculture, Food and Rural Affairs and the Seoul Metropolitan Government. The awards ceremony will be streamed live via the link here. The announcement of the list and individual awards can be followed via the 50 Best social media channels, with the livestream beginning at 20:00 Korea time.

Media Centre:
https://mediacentre.theworlds50best.com/

SK keyfoundry Launches 3D Hall-effect Sensor Technology Capable of Measuring Speed and Direction

SEOUL, South Korea, March 6, 2025 /PRNewswire/ — SK keyfoundry, an 8-inch pure-play foundry in Korea, announced today that it offers a new 3D Hall-effect sensor technology that can measure speed and direction through three-dimensional magnetic field detection for its foundry customers.

The Hall-effect sensor is a device that measures the strength of a magnetic field using the Hall-effect, which detects the voltage difference generated when a conductor or semiconductor passes through a magnetic field. The measured magnetic field is utilized in applications that leverage the position, speed, rotation, direction, and current of devices.

SK keyfoundry has provided a variety of products using existing 1D (one-dimensional) and 2D (two-dimensional) Hall-effect sensors, and this new 3D Hall-effect sensor integrates both Vertical and Planar Hall-effect sensors on a single chip. It features enhanced sensitivity beyond that of existing 2D products, enabling real-time measurement of minute three-dimensional direction and speed changes with rapid response times.

Another important feature of the 3D Hall-effect sensor provided by SK keyfounrdry is that it can be designed to easily integrate into customer products by adding masks to existing processes. Additionally, the integration of the 3D Hall-effect sensor is offered across multiple nodes in the range of 0.13μm to 0.18μm while maintaining electrical characteristics.

The new 3D Hall-effect sensor is expected to be utilized in various fields. In particular, it can be applied in the automotive sector for safe driving assistance and autonomous driving systems, in consumer electronics for smart appliances and gaming consoles, and in industrial automation for robot control, drones, virtual reality, augmented reality, and wearable devices.

Derek D. Lee, the CEO of SK keyfoundry, stated, “The newly launched 3D Hall-effect sensor technology is expected to be utilized in the design of products across various industries, including home appliances, automotive, robotics, and drones, due to its high sensitivity and ability to detect minute three-dimensional movements.” He added, “We plan to support our customers in integrating more diverse functions into a single semiconductor through ongoing technology openness.”

About SK keyfoundry

Headquartered in Korea, SK keyfoundry provides specialty Analog and Mixed-Signal foundry services for semiconductor companies to serve a wide range of applications in the consumer, communications, computing, automotive and industrial industries. With a broad range of technology portfolios and process nodes, SK keyfoundry has the flexibility and capability to meet the ever-evolving needs of semiconductor companies across the globe. Please visit https://www.skkeyfoundry.com for more information.

Apollo Group TV Expands Payment Options Making Premium Streaming More Accessible with Raydium Solutions

BOSTON, March 6, 2025 /PRNewswire/ — In a strategic partnership with Raydium Solutions, Apollo Group TV is making premium streaming more accessible by introducing credit card payments for the first time. Previously limited to Bitcoin transactions, this major shift allows more users to enjoy secure, high-quality streaming with greater flexibility. As a leading provider of IPTV services, Apollo Group TV continues to redefine home entertainment with a vast selection of content, cutting-edge streaming technology, and customer-focused innovations.


Unmatched Variety of Live TV and On-Demand Content

Apollo Group TV offers an impressive catalog of 24,000+ live channels and 95,000+ Video-on-Demand (VOD) titles, spanning movies, TV series, news, sports, and international programming. With access to premium channels across multiple genres, subscribers can enjoy the best in live television, blockbuster films, and exclusive series all in one place.

Designed to meet the needs of a diverse audience, Apollo Group TV ensures that viewers always have access to the latest Hollywood hits, classic films, trending TV shows, and live sports events without limitations.

Expanding Payment Options: Now Accepting Credit Cards

Through its collaboration with Raydium Solutions, Apollo Group TV has expanded its payment options, now accepting credit cards alongside cryptocurrency payments. This move reflects Apollo TV’s commitment to making its premium IPTV service more accessible to a wider audience.

“With consumer demand for seamless and secure transactions rising, expanding payment methods was a natural step,” said a spokesperson from Raydium Solutions, the technology partner supporting this transition. “This collaboration ensures that more users can access Apollo TV’s premium streaming service with ease.”

High-Definition Streaming with Advanced Technology

Apollo Group TV delivers an unparalleled viewing experience, offering crystal-clear HD and 4K resolution for a cinematic feel at home. The platform utilizes anti-freeze technology to eliminate buffering, ensuring smooth and uninterrupted playback.

With a 99.9% uptime guarantee, Apollo TV users can rely on a stable, high-performance streaming service at any time—whether watching live TV, sports, or on-demand content.

Seamless User Experience & Smart Device Compatibility

Apollo Group TV enhances navigation with an Electronic Program Guide (EPG) TV Guide, making it easy to browse and manage content. The intuitive interface allows users to switch between channels effortlessly and discover new content.

The platform is compatible with a wide range of devices, including smart TVs, streaming boxes, mobile devices, and tablets, ensuring maximum flexibility for subscribers.

Reliable Customer Support and Lifetime Assistance

Apollo Group TV is dedicated to customer satisfaction, offering 24/7 live chat support to assist with technical issues, account management, and content recommendations.

Through its strategic technology partnership with Raydium Solutions, Apollo TV ensures that its platform remains highly secure, accessible, and future-ready, continuously improving the user experience.

Join the Future of Streaming with Apollo Group TV

With its expansive content library, advanced streaming technology, and newly expanded payment options, Apollo Group TV is setting new standards in digital entertainment.

For more details on subscription plans and the latest updates, visit ApolloTVsGroup.com.

About Apollo Group TV

Apollo Group TV is a leading IPTV streaming service, providing access to thousands of live TV channels, movies, and series in high-definition quality. With a commitment to innovation, top-tier customer support, and a seamless viewing experience, Apollo Group TV continues to revolutionize premium home entertainment.